EMA Recommends Granting a Conditional Marketing Authorisation for Belantamab Mafodotin
First antibody-drug conjugate for multiple myeloma patients with limited treatment options
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
EMA Recommends Granting a Conditional Marketing Authorisation for Avapritinib
It is intended for the treatment of adult patients with unresectable or metastatic GIST harbouring the PDGFR alpha D842V mutation
EMA Recommends Extension of Indications for Durvalumab
New indication concerns first-line treatment of adults with extensive-stage small cell lung cancer
2020 Cancer Incidence and Mortality in EU-27 Countries
The effects of COVID-19 pandemic are not reflected in the 2020 estimates
Italian Association of Oncology Nurses Maps the Situation of Cancer Patients Who are Self-Isolated at Home
An interim analysis of survey data in the context of the COVID-19 pandemic
Incidence, Relative Risk and Risk Factors for Chronic Comorbidities in Long-Term Survivors of AYA Cancer
Findings from a cohort of 6,778 survivors of adolescent and young adult cancer
Survivorship and Immune Checkpoint Inhibitors
Findings from a series of long-term survivors with melanoma, renal cell carcinoma and non–small cell lung cancer
Consensus on Conceptual Framework for Precision Cancer Medicine in Germany
Collaborative efforts of fourteen comprehensive cancer centres within the German Cancer Aid network
Pregnancy is Safe After Early Breast Cancer in Young Women with Germline BRCA Mutations
Findings provide reassurance about feasibility and safety of future fertility
Assessment of Patients’ Perspective on the Consequences of the COVID-19 Pandemic on Cancer Care
Results from the survey among 5302 cancer patients in the Netherlands
New Measures to Avoid Handling Errors with Leuprorelin Depot Medicines
The errors reported included incorrect use of the needle or syringe, causing the medicine to leak from the syringe, and failure to inject leuprorelin properly
FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes
Cedazuridine was investigated in ASTX727-01-B and ASTX727-02 trials